PortalPublikationenTranslating gammadelta (γδ) T cells and their receptors into...

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

Standard

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. / Sebestyen, Zsolt; Prinz, Immo; Déchanet-Merville, Julie; Silva-Santos, Bruno; Kuball, Jurgen.

in: NAT REV DRUG DISCOV, Jahrgang 19, Nr. 3, 03.2020, S. 169-184.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Sebestyen, Z, Prinz, I, Déchanet-Merville, J, Silva-Santos, B & Kuball, J 2020, 'Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies', NAT REV DRUG DISCOV, Jg. 19, Nr. 3, S. 169-184. https://doi.org/10.1038/s41573-019-0038-z

APA

Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., & Kuball, J. (2020). Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. NAT REV DRUG DISCOV, 19(3), 169-184. https://doi.org/10.1038/s41573-019-0038-z

Vancouver

Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. NAT REV DRUG DISCOV. 2020 Mär;19(3):169-184. https://doi.org/10.1038/s41573-019-0038-z

Bibtex

@article{8cd151b358b54eff8a2f70891d9d2e3d,
title = "Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies",
abstract = "Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.",
keywords = "Cell- and Tissue-Based Therapy/methods, Humans, Immunotherapy/methods, Neoplasms/immunology, Receptors, Antigen, T-Cell, gamma-delta/immunology, T-Lymphocytes/immunology",
author = "Zsolt Sebestyen and Immo Prinz and Julie D{\'e}chanet-Merville and Bruno Silva-Santos and Jurgen Kuball",
year = "2020",
month = mar,
doi = "10.1038/s41573-019-0038-z",
language = "English",
volume = "19",
pages = "169--184",
journal = "NAT REV DRUG DISCOV",
issn = "1474-1776",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

AU - Sebestyen, Zsolt

AU - Prinz, Immo

AU - Déchanet-Merville, Julie

AU - Silva-Santos, Bruno

AU - Kuball, Jurgen

PY - 2020/3

Y1 - 2020/3

N2 - Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.

AB - Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively, but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently, there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review, we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.

KW - Cell- and Tissue-Based Therapy/methods

KW - Humans

KW - Immunotherapy/methods

KW - Neoplasms/immunology

KW - Receptors, Antigen, T-Cell, gamma-delta/immunology

KW - T-Lymphocytes/immunology

U2 - 10.1038/s41573-019-0038-z

DO - 10.1038/s41573-019-0038-z

M3 - SCORING: Review article

C2 - 31492944

VL - 19

SP - 169

EP - 184

JO - NAT REV DRUG DISCOV

JF - NAT REV DRUG DISCOV

SN - 1474-1776

IS - 3

ER -